journal
https://read.qxmd.com/read/37529087/management-of-mixed-warm-cold-autoimmune-hemolytic-anemia-a-case-report-and-review-of-current-literature
#21
Elliot C Smith, Nabeel Kahwash, Siavash Piran
BACKGROUND: Mixed warm/cold autoimmune hemolytic anemia (AIHA) is a rare diagnostic entity with limited therapeutic options. Previous literature has described the diagnostic difficulty in this pathology and the limited response rates to corticosteroids. Furthermore, there is limited evidence regarding the use of rituximab in this condition. METHODS: Alongside our case report, we conducted a scoping review of case reports/case series describing mixed AIHA, their treatment, and clinical outcomes since 2000...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37457315/a-rare-case-of-blastic-plasmacytoid-dendritic-cell-neoplasm-occurred-in-postchemotherapy-of-breast-cancer
#22
Jiankun Tong, Sergei Aksenov, Beth M Siegel, Lihong Wei, William H Rodgers
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells. BPDCN typically presents with skin lesions and may involve peripheral blood, bone marrow, lymph nodes, or extranodal sites. It usually arises de novo, and some BPDCN cases are associated with or develop into myeloid neoplasms. Here, we report a case of a 57-year-old female presenting with cervical lymphadenopathy and skin rashes during the COVID-19 pandemic in 2021 following multiple types of postmastectomy therapy for breast cancer...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37434656/detection-of-an-mn1-etv6-gene-fusion-in-a-case-of-acute-myeloid-leukemia-with-erythroid-differentiation-a-case-report-and-review-of-the-literature
#23
Lauren A Choate, Liuyan Jiang, Mariam I Stein, Wei Shen, Linda B Baughn, Jess F Peterson
The MN1::ETV6 gene fusion resulting from t(12;22)(p13;q12) has been rarely reported in myeloid neoplasms. We describe a 69-year-old male with newly diagnosed acute myeloid leukemia (AML) with erythroid differentiation and t(12;22)(p13;q12) demonstrated by conventional chromosome studies. Subsequent fluorescence in situ hybridization studies demonstrated a balanced ETV6 gene rearrangement (at 12p13). To further characterize this translocation, whole-genome sequencing was performed which confirmed t(12;22) with breakpoints involving the MN1 and ETV6 genes...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37434655/fat-embolization-syndrome-secondary-to-steroid-treatment-in-a-case-of-sickle-cell-vaso-occlusive-crisis
#24
Ram Prakash Thirugnanasambandam, Farish Mohamed Maraikayar, Marie Liu, Khalid Elbashir, John Muthu
Fat embolization syndrome (FES) is often seen as a complication of fractures and has been known to cause respiratory failure, rashes of the skin, thrombocytopenia, and neurological damage. Nontraumatic FES is uncommon and occurs due to bone marrow necrosis. Vaso-occlusive crisis in sickle cell patients secondary to steroid therapy is a rare entity and not widely acknowledged. We report a case of FES secondary to steroid therapy administered for a patient with intractable migraine. FES is an uncommon yet serious complication that occurs due to bone marrow necrosis and is usually associated with increased mortality or damaging neurologic sequelae for the surviving patient...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37424536/friend-or-foe-factor-xii-deficiency-discovered-incidentally-during-management-of-nstemi
#25
Patrick J Beck, John Benfield, Joshua Morales
Factor XII (FXII) deficiency is a rare coagulopathy that typically goes undiagnosed due to the lack of abnormal bleeding or thrombosis. However, the accompanying prolonged activated partial thromboplastin time (aPTT) can create difficulties with maintaining therapeutic anticoagulation in the setting of acute coronary syndrome (ACS). Here, we present the case of a 52-year-old man presenting with chest pain and diagnosed with an NSTEMI but also found with a prolonged baseline aPTT ultimately secondary to FXII deficiency...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37408875/ige-plasma-cell-leukemia-harboring-t-11-14-and-1q-amplification
#26
Wataru Nakahara, Takahito Ogawa, Hitomi Matsunaga, Yuki Iwasa, Momoka Horita, Mako Ikeda, Mizuki Asako, Sadaharu Iio, Yuki Iwama, Kazumasa Oka, Shuji Ueda
IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37388486/refractory-immune-thrombocytopenic-purpura-with-abdominal-splenosis-a-complex-case
#27
Joseph F Mort, Danh T Tran, Sean C Dougherty, Robert Zielinski, Michael D Williams, Kelly M Davidson
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia resulting from immune-mediated platelet destruction via antiplatelet antibodies and T cells. Medical management of ITP includes corticosteroids and multiple other adjunct therapies, with splenectomy generally being reserved for severe, refractory cases. In this clinical case report, we describe the evaluation of a 35-year-old male with a history of prior traumatic splenic injury who presented to the emergency department endorsing easy bruising and a petechial rash, ultimately found to have severe thrombocytopenia...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37323813/two-refractory-immune-thrombocytopenia-case-reports-showing-responsiveness-to-fostamatinib
#28
Vanessa Innao, Rosalba Donatella Calogero, Fabrizio Lo Presti, Ugo Consoli
Immune thrombocytopenia (ITP) is immune-mediated platelet loss due to increased destruction and insufficient production. Treatment guidelines provide for first-line steroid-based therapies followed by thrombopoietin receptor agonists (TPO-RAs) and fostamatinib for chronic ITP. Fostamatinib demonstrated efficacy in phase 3 FIT trials (FIT1 and FIT2) mainly in second-line therapy resulting in the maintenance of stable platelet values. Here, we describe two patients with extremely heterogeneous characteristics that responded to fostamatinib after two and nine previous treatments...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37303483/solitary-plasmacytoma-of-the-breast-a-case-of-an-uncommon-breast-neoplasm
#29
Sean McCormack, Eyad Hamad, Amar Hamad
Plasmacytoma is a rare cancer that originates from a single plasma cell and is characterized by the abnormal proliferation of monoclonal plasma cells. It is typically localized in a single area of the body, most commonly in the bone or soft tissue. Solitary plasmacytoma can be further classified as either solitary plasmacytoma of bone (SPB) or solitary extramedullary plasmacytoma (SEP or EMP). Diagnosis may be delayed in symptomatically silent plasmacytomas, but early diagnosis and prompt treatment are crucial for the management of this disease...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37303482/incidental-diagnosis-of-oligosymptomatic-bilateral-perirenal-erdheim-chester-disease-during-emergency-investigation-for-covid-19-infection
#30
Juliano Cordova Vargas, Caio Cardozo, Renata Stanzione, Lucas Fiore, Felipe D'Almeida Costa, Rodrigo Fonseca Abreu, Nelson Hamerschlak, Guilherme Perini
Erdheim-Chester disease (ECD), a rare form of non-Langerhans histiocytosis, is a multisystem disorder. The case reported here refers to a 49-year-old man presenting at the emergency room with respiratory symptoms. While undergoing diagnostic tests for COVID-19 infection, tomography revealed asymptomatic bilateral perirenal tumors, while renal function remained unaltered. ECD was suggested as an incidental diagnosis and confirmed by core needle biopsy. This report provides a brief description of the clinical, laboratory, and imaging findings in this case of ECD...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37197195/pyruvate-kinase-deficiency-causing-priapism
#31
Vinay Hanyalu Shankar, Bharadwaj Adithya-Sateesh, Nicole Gousy, Girma Ayele, Freyr Petursson, Rediet Atalay, Miriam Michael
Pyruvate kinase deficiency (PKD) is an autosomal recessive defect of the enzyme pyruvate kinase (PK) which is involved in catalyzing a reaction that produces ATP in the glycolytic pathway. It is the most common defect of the glycolytic pathway associated with congenital anemia. Patients usually present with signs of chronic hemolytic anemia such as hyperbilirubinemia, splenomegaly, reticulocytosis, and gallstones; the presentation can vary by age. Diagnosis is usually made by demonstration of decreased PK enzymatic activity in a spectrophotometric assay and on the detection of mutations in the PK-LR gene...
2023: Case Reports in Hematology
https://read.qxmd.com/read/37123466/imatinib-resistance-in-chronic-myeloid-leukemia-associated-with-a-d363g-bcr-abl1-kinase-domain-mutation
#32
Stephen E Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which occur at seven codons within this region. A case of CML is described in which presence of a rare D363G BCR::ABL1 KDM resulted in a suboptimal response to frontline imatinib. Switching to dasatinib resulted in achieving a sustained major molecular response that was maintained after a subsequent switch to bosutinib due to the side effects...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36950529/rapid-onset-severe-immune-thrombocytopenia-following-mrna-covid-19-vaccine-in-a-young-patient
#33
Jorge Avila, Huseyin Berk Degirmenci, Pamela Contreras Chavez, Elisabeth M Battinelli, Jorge Fleisher
The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36879894/vexas-syndrome-in-a-patient-with-myeloproliferative-neoplasia
#34
Janne Austestad, Tor Magne Madland, Miriam Sandnes, Torjan Magne Haslerud, Andreas Benneche, Håkon Reikvam
VEXAS syndrome stands for vacuoles, E1 enzyme, X -linked, autoinflammatory, somatic syndrome. The syndrome is a combined hematological and rheumatological condition caused by a somatic mutation in the UBA1 . There is an association between VEXAS and hematological conditions such as myelodysplastic syndrome (MDS), monoclonal gammopathies of uncertain conditions (MGUS), multiple myeloma (MM), and monoclonal B-cell lymphoproliferative conditions. There are not many descriptions of patients having VEXAS in combination with myeloproliferative neoplasm (MPN)...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36879893/multilineage-lymphoblastic-lymphoma-as-an-initial-presentation-of-mixed-phenotype-acute-leukemia
#35
Mako Ikeda, Wataru Nakahara, Mizuki Asako, Yuka Umeki, Yoshiki Matsuoka, Takuya Terakawa, Hitomi Matsunaga, Yuki Iwasa, Riko Saito, Yuki Iwama, Takahiro Matsui, Kazumasa Oka, Shuji Ueda
Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36852298/a-rare-case-of-renal-thrombotic-microangiopathy-and-focal-segmental-glomerulosclerosis-secondary-to-plasma-cell-leukemia
#36
Justin Komisarof, Jessica Forman, Bruce Goldman, Chauncey Syposs, Frank Passero, Ellie Garbade
Plasma cell dyscrasias are a subset of hematological malignancies involving the production of monoclonal immunoglobulins. This spectrum of disorders includes asymptomatic conditions such as monoclonal gammopathy of unknown significance as well as extremely aggressive malignancies such as plasma cell leukemia. Monoclonal gammopathies are occasionally associated with renal failure, which can occur via many pathophysiological processes. The most common of these is light chain cast nephropathy, but many rare renal complications exist, including thrombotic microangiopathy (TMA) and focal segmental glomerulosclerosis (FSGS)...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36846547/ehrlichiosis-associated-hemophagocytic-lymphohistiocytosis-a-case-series-and-review-of-the-literature
#37
Kassem Hammoud, Robert Fulmer, Megan Hamner, Wissam El Atrouni
BACKGROUND: Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36793393/whim-syndrome-first-reported-case-in-a-patient-of-african-ancestry
#38
Jinal Gandhi, Michelle H Lee, Lynsie Adams, Tara Shrout Allen, Julie Li, Camille Vanessa Edwards
BACKGROUND: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of myelokathexis. The pathophysiology of WHIM syndrome is due to an autosomal dominant gain of function mutation in the CXCR4 chemokine receptor resulting in increased activity that impairs neutrophil migration from the bone marrow into the peripheral blood...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36643956/primary-cardiac-lymphoma-presenting-with-thrombocytopenia-right-heart-failure-and-cardiogenic-shock
#39
Samantha Kurniawan, Gita Mathur, Yvonne Bogun, Giselle Kidson-Gerber
Primary cardiac lymphoma (PCL) is a rare, potentially fatal subtype of non-Hodgkin's lymphoma. Thrombocytopenia has also infrequently been reported in association with other primary cardiac tumours and can add substantial morbidity to an already life-threatening diagnosis if present. We report a rare case of a 70-year-old man who presented with thrombocytopenia (91 × 109 /L) and progressive right heart failure. Transthoracic echocardiogram revealed a large 8 × 4 cm right atrial mass with severe tricuspid obstruction, confirmed as PCL on subsequent endomyocardial biopsy and immunohistochemistry...
2023: Case Reports in Hematology
https://read.qxmd.com/read/36619478/relapse-of-npm1-mutated-aml-with-extramedullary-manifestation-17%C3%A2-years-after-allogeneic-hematopoietic-stem-cell-transplantation
#40
Jan Braune, Kathrin Rieger, Olga Blau, Ulrich Keller, Lars Bullinger, Jan Krönke
The majority of patients with acute myeloid leukemia (AML) with the NPM1 mutation achieve remission with intensive chemotherapy. However, many patients subsequently relapse, which occurs frequently within the first 2-3 years after therapy, while late relapse after more than 10 years is rare and can also represent secondary/therapy-associated AML without the NPM1 mutation. Here, we present a case of NPM1 -mutated AML that developed medullary and extramedullary relapse 17 years after allogeneic stem cell transplantation, maintaining the NPM1 mutation and all other genetic alterations detected at first diagnosis...
2022: Case Reports in Hematology
journal
journal
43910
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.